These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2106765)

  • 21. Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.
    Chrisp P; Lewis NJ; Milne RJ
    Pharmacoeconomics; 1992 Feb; 1(2):124-45. PubMed ID: 10146941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [How to evaluate the cost/effectiveness ratio of different therapies of coronary disease].
    Roquebrune JP; L'Héritier P; Gibelin P; Baudouy M; Camous JP; Blanc P; Bossan S; Morand P
    Arch Mal Coeur Vaiss; 1992 Feb; 85(2):239-44. PubMed ID: 1348616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
    Hay JW; Sterling KL
    Pharmacoeconomics; 2005; 23(2):133-41. PubMed ID: 15748088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
    Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new method of estimating cost effectiveness of cholesterol reduction therapy for prevention of heart disease.
    Kinlay S; O'Connell D; Evans D; Halliday J
    Pharmacoeconomics; 1994 Mar; 5(3):238-48. PubMed ID: 10146898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the evidence. Cholesterol and coronary heart disease screening & treatment.
    Turner-Boutle M; Sheldon T; Smith GD; Ebrahim S
    Health Serv J; 1998 Feb; 108(5593):36-7. PubMed ID: 10177607
    [No Abstract]   [Full Text] [Related]  

  • 27. [Basic principles of cost-benefit analysis in long-term treatment of risk factors].
    Szucs TD; Gutzwiller F
    Schweiz Med Wochenschr; 1998 Dec; 128(49):1958-64. PubMed ID: 9887476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of populationwide educational approaches to reduce serum cholesterol levels.
    Tosteson AN; Weinstein MC; Hunink MG; Mittleman MA; Williams LW; Goldman PA; Goldman L
    Circulation; 1997 Jan; 95(1):24-30. PubMed ID: 8994412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Costs and health consequences of cholesterol screening for asymptomatic older Americans.
    Garber AM; Littenberg B; Sox HC; Wagner JL; Gluck M
    Arch Intern Med; 1991 Jun; 151(6):1089-95. PubMed ID: 1904212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Asymptomatic hypercholesterolemia: a clinical policy review. The Toronto Working Group on Cholesterol Policy.
    J Clin Epidemiol; 1990; 43(10):1028-121. PubMed ID: 2120391
    [No Abstract]   [Full Text] [Related]  

  • 31. Decline of coronary heart disease mortality in The Netherlands from 1978 to 1985: contribution of medical care and changes over time in presence of major cardiovascular risk factors.
    Bots ML; Grobbee DE
    J Cardiovasc Risk; 1996 Jun; 3(3):271-6. PubMed ID: 8863098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK.
    Scuffham PA; Chaplin S
    Pharmacoeconomics; 2004; 22(8):525-35. PubMed ID: 15217308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholesterol screening should be targeted.
    Garber AM
    Am J Med; 1997 Feb; 102(2A):26-30. PubMed ID: 9217583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.
    Goldman L; Weinstein MC; Goldman PA; Williams LW
    JAMA; 1991 Mar; 265(9):1145-51. PubMed ID: 1899896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefits and costs of medical nutrition therapy by registered dietitians for patients with hypercholesterolemia. Massachusetts Dietetic Association.
    McGehee MM; Johnson EQ; Rasmussen HM; Sahyoun N; Lynch MM; Carey M
    J Am Diet Assoc; 1995 Sep; 95(9):1041-3. PubMed ID: 7657908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment and prevention of coronary heart disease by lowering serum cholesterol levels; from the pioneer work of C.D. de Langen to the third "Dutch Consensus on Cholesterol".
    Jukema JW; Simoons ML
    Acta Cardiol; 1999 Jun; 54(3):163-8. PubMed ID: 10478274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholesterol screening in asymptomatic adults, revisited. Part 2.
    Garber AM; Browner WS; Hulley SB
    Ann Intern Med; 1996 Mar; 124(5):518-31. PubMed ID: 8602715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
    Johannesson M
    Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway.
    Cook JR; Yin D; Alemao E; Davies G; Krobot KJ; Veltri E; Lipka L; Badia X
    Pharmacoeconomics; 2004; 22 Suppl 3():49-61. PubMed ID: 15669153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain.
    Plans-Rubió P
    Pharmacoeconomics; 1998 May; 13(5 Pt 2):623-43. PubMed ID: 17165328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.